Sponsor content

Collaborative Research and Licensing Opportunity: HIV targets CD62L on central memory T cells through viral envelope glycans for adhesion and induces selectin shedding for viral release

NIAID researchers have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.

Upvote 1 Comment

       Despite the success of anti-retroviral therapy in controlling HIV in infected individuals, treatment is less effective at eliminating HIV viral reservoirs.  The nature of HIV reservoirs and the factors controlling their size and release are a major research focus for achieving a cure for HIV/AIDS.

       NIAID researchers have identified L-selectin/CD62L as a new target for treating HIV by inhibiting viral release from infected cells. They found that shedding of CD62L on T cells is required for the efficient release of HIV virus from infected cells. Further, they have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.

Potential Commercial Applications: 

  • New target for HIV therapeutic development.

Competitive Advantages: 

  • This invention comprises a method of treating HIV using therapeutics geared toward viral release and entry, distinguishing it from other antiviral candidates with its method of action.
  • CD62L is a new target for HIV

Development Stage:  In vitro studies; Proof-of-concept studies.

Inventors: Peter Sun, Joseph Kononchik, Joanna Ireland, Ruiping Wang, all from NIAID, NIH

Intellectual Property:  HHS Reference No. E-261-2015/0 - PCT No. PCT/US2016/068713, filed 12/27/2016.

Licensing and Collaborative Research Opportunity:The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in licensing or collaborative research to further co-develop this technology. For opportunities, please contact Chris Kornak, J.D., 240-627-3705, Chris.Kornak@nih.gov

Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
25 Contributions
14 Followers
1 Following

No comments yet.